Thrivent Financial For Lutherans raised its position in Boston Scientific Corporation (NYSE:BSX) by 2.9% during the second quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 51,470 shares of the medical equipment provider’s stock after buying an additional 1,430 shares during the period. Thrivent Financial For Lutherans’ holdings in Boston Scientific Corporation were worth $1,427,000 as of its most recent SEC filing.

A number of other large investors have also recently added to or reduced their stakes in BSX. FMR LLC grew its position in Boston Scientific Corporation by 7.6% during the 1st quarter. FMR LLC now owns 184,708,390 shares of the medical equipment provider’s stock worth $4,593,698,000 after acquiring an additional 13,105,596 shares during the last quarter. BlackRock Inc. raised its position in Boston Scientific Corporation by 4.6% in the 2nd quarter. BlackRock Inc. now owns 100,184,511 shares of the medical equipment provider’s stock worth $2,777,113,000 after purchasing an additional 4,439,966 shares during the last quarter. Vanguard Group Inc. raised its position in Boston Scientific Corporation by 4.0% in the 1st quarter. Vanguard Group Inc. now owns 91,134,744 shares of the medical equipment provider’s stock worth $2,266,521,000 after purchasing an additional 3,503,965 shares during the last quarter. Geode Capital Management LLC raised its position in Boston Scientific Corporation by 7.9% in the 1st quarter. Geode Capital Management LLC now owns 12,120,374 shares of the medical equipment provider’s stock worth $300,963,000 after purchasing an additional 888,331 shares during the last quarter. Finally, Jennison Associates LLC raised its position in Boston Scientific Corporation by 405.3% in the 2nd quarter. Jennison Associates LLC now owns 10,639,290 shares of the medical equipment provider’s stock worth $294,921,000 after purchasing an additional 8,533,655 shares during the last quarter. Hedge funds and other institutional investors own 90.44% of the company’s stock.

BSX has been the topic of several analyst reports. BidaskClub lowered shares of Boston Scientific Corporation from a “hold” rating to a “sell” rating in a report on Saturday, August 26th. Needham & Company LLC increased their price target on Boston Scientific Corporation from $30.00 to $32.00 and gave the company a “buy” rating in a research note on Thursday, June 22nd. Royal Bank Of Canada restated a “buy” rating and issued a $31.00 price target on shares of Boston Scientific Corporation in a research report on Friday, September 1st. Stifel Nicolaus reaffirmed a “buy” rating and set a $32.00 price objective on shares of Boston Scientific Corporation in a research note on Sunday, July 30th. Finally, Zacks Investment Research downgraded Boston Scientific Corporation from a “hold” rating to a “sell” rating in a report on Tuesday, July 11th. One investment analyst has rated the stock with a sell rating, five have assigned a hold rating, fourteen have assigned a buy rating and one has assigned a strong buy rating to the company’s stock. The stock currently has an average rating of “Buy” and an average price target of $30.12.

Boston Scientific Corporation (NYSE:BSX) opened at 29.47 on Tuesday. Boston Scientific Corporation has a one year low of $19.67 and a one year high of $29.47. The stock’s 50 day moving average is $27.99 and its 200 day moving average is $26.89. The firm has a market cap of $40.44 billion, a price-to-earnings ratio of 52.72 and a beta of 1.09.

Boston Scientific Corporation (NYSE:BSX) last issued its quarterly earnings data on Thursday, July 27th. The medical equipment provider reported $0.32 earnings per share for the quarter, topping the Zacks’ consensus estimate of $0.31 by $0.01. The firm had revenue of $2.26 billion for the quarter, compared to analyst estimates of $2.21 billion. Boston Scientific Corporation had a return on equity of 23.62% and a net margin of 9.04%. The business’s quarterly revenue was up 6.2% compared to the same quarter last year. During the same period last year, the company earned $0.27 EPS. On average, analysts predict that Boston Scientific Corporation will post $1.26 earnings per share for the current fiscal year.

In other news, CFO Daniel J. Brennan sold 92,158 shares of Boston Scientific Corporation stock in a transaction dated Tuesday, July 11th. The shares were sold at an average price of $27.48, for a total transaction of $2,532,501.84. Following the sale, the chief financial officer now owns 235,421 shares of the company’s stock, valued at approximately $6,469,369.08. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, SVP Wendy Carruthers sold 12,433 shares of Boston Scientific Corporation stock in a transaction dated Thursday, August 3rd. The shares were sold at an average price of $26.75, for a total transaction of $332,582.75. The disclosure for this sale can be found here. In the last quarter, insiders sold 276,318 shares of company stock worth $7,567,967. 0.74% of the stock is currently owned by company insiders.

TRADEMARK VIOLATION NOTICE: This piece of content was posted by Watch List News and is the property of of Watch List News. If you are viewing this piece of content on another website, it was illegally copied and republished in violation of international copyright legislation. The correct version of this piece of content can be accessed at https://www.watchlistnews.com/thrivent-financial-for-lutherans-has-1-43-million-position-in-boston-scientific-corporation-bsx/1604823.html.

About Boston Scientific Corporation

Boston Scientific Corporation is a developer, manufacturer and marketer of medical devices that are used in a range of interventional medical specialties. The Company offers its products by seven businesses: Interventional Cardiology, Cardiac Rhythm Management, Endoscopy, Peripheral Interventions, Urology and Pelvic Health, Neuromodulation, and Electrophysiology.

Want to see what other hedge funds are holding BSX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Boston Scientific Corporation (NYSE:BSX).

Institutional Ownership by Quarter for Boston Scientific Corporation (NYSE:BSX)

Receive News & Ratings for Boston Scientific Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Boston Scientific Corporation and related companies with Analyst Ratings Network's FREE daily email newsletter.